NASDAQ · Biotechnology

ProQR Therapeutics N.V. (PRQR) Stock

$1.63 +3.82% NASDAQ: PRQR Healthcare

Valuation

MetricValue
Price$1.63
Market Cap$171.65M
P/E Ratio-3.68
P/B Ratio2.02
P/S Ratio8.27
EPS (TTM)$-0.64
52-Week High$3.10
52-Week Low$1.33
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-68.44%
ROA-31.76%
ROCE-43.82%
Gross Margin89.75%
Operating Margin-3.46%
Net Margin-228.29%
Debt/Equity0.17
Current Ratio3.13

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$4.0M$7.0M$19.0M$15.0M
Operating Profit$-57.0M$-65.0M$-32.0M$-30.0M$-42.0M
Net Profit$-61.0M$-64.0M$-28.0M$-28.0M$-41.0M
EPS$-0.96$-0.91$-0.35$-0.34$-0.38
Op Margin-4285.4%-1813.0%-489.1%-161.2%-275.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$238.0M$183.0M$152.0M$174.0M$132.0M
Total Liabilities$110.0M$112.0M$107.0M$82.0M$74.0M
Cash$213.0M$101.0M$131.0M$155.0M$109.0M
Borrowings$69.0M$23.0M$22.0M$16.0M$16.0M

Latest News

Daily – Vickers Top Buyers & Sellers for 07/14/2026 Argus Research · Jul 14, 2026 ProQR Registers Shares for Resale by Investor MT Newswires · Jul 6, 2026 Chardan Research Adjusts ProQR Therapeutics Price Target to $3 From $4, Maintains Buy Rating MT Newswires · Jun 26, 2026 ProQR Therapeutics Says Phase 1 Trial of Liver Drug Candidate Meets Primary Endpoint MT Newswires · Jun 25, 2026 ProQR Therapeutics Prices $50 Million Underwritten Registered Direct Offering MT Newswires · Jun 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-26.0M$-69.0M$22.0M$-36.0M$-53.0M
Investing Cash Flow$-1.0M$-1.0M$3.0M$-5.0M$-2.0M
Financing Cash Flow$2.0M$0$0$0$0
Net Cash Flow$112.0M$-93.0M$24.0M$30.0M$-57.0M
Free Cash Flow$-26.0M$-69.0M$20.0M$-38.0M$-54.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.63
EV / EBITDA-1.32
FCF Yield-32.75%
Quick Ratio3.49
Interest Coverage-42.00
Return 1Y-31.45%
Return 3Y-2.86%
Return 5Y-69.26%

Ownership

Insiders Held14.22%
Institutions Held38.63%
Institutions Float Held45.03%
Institutional HolderSharesReport Date
Adage Capital Partners GP L.L.C.6,253,4672026-03-31
Privium Fund Management B.V.5,467,1492026-03-31
Aberdeen Group plc3,316,9652026-03-31
Affinity Asset Advisors, Llc2,454,2782026-03-31
Sio Capital Management, LLC1,954,7152026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACHVAchieve Life Sciences, Inc. $7.41 +3.06% -4.67 $760.70M 0.00%
ALLOAllogene Therapeutics, Inc. $1.46 +4.29% -2.24 $503.96M 0.00%
ARCTArcturus Therapeutics Holdings Inc. $13.74 +6.76% -3.91 $390.53M 0.00%
CAPRCapricor Therapeutics, Inc. $7.83 -2.25% -3.93 $450.31M 0.00%
EDITEditas Medicine, Inc. $2.95 +4.04% -3.50 $453.45M 0.00%

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V. is led by CEO Daniel Anton de Boer, publicly traded since 2014.

ProQR Therapeutics N.V. (PRQR) stock trades at $1.63 with a market capitalization of $171.65M. The stock is valued at a price-to-earnings (P/E) ratio of -3.68, price-to-book of 2.02, price-to-sales of 8.27. Over the past 52 weeks the stock has ranged between $1.33 and $3.10, and currently trades 47.4% below its 52-week high.

On profitability, ProQR Therapeutics N.V. generates a return on equity (ROE) of -68.44%, return on capital employed of -43.82%, an operating margin of -3.46%, a net profit margin of -228.29%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides